Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Angiotensin type-1 receptor (AT1R) blockers (ARBs) have been recognized recently as regulators of glucose and lipid metabolism in adipocytes and adipose tissue.Moreover telmisartan and irbesartan have been recognized recently as regulators of glucose metabolism. For ARB losartan, the results were controversial. To confirm its effect on glucose metabolism, we designed and performed a prospective, randomized and controlled study in subjects with type 2 diabetes and nephropathy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Insulin; Losartan

Criteria

Inclusion Criteria:

• Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L

• 2h plasma glucose level of 7.5-13 mmol/L

• Body mass index (BMI) of 22 kg/m2

• Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is >150mg.

• Informed consent

Exclusion Criteria:

• Type1 diabetes or nondiabetic renal disease